Best practices in pediatric TB testing - on demand webinar

Responsive image

Thank you

Thank you for your interest in QIAGEN microbiome workflow solutions.
A sales representative will contact you soon with your tailored discount offer.

Register here to watch the webinar today!

Address1

Referral source (URL)

Form ID

First Name*

Last Name*

Email address *

City*

Country*

State or Province*

Zip or Postal Code

Organization*

Job Profession*

What test do you most often use as part of your clinical assessment for diagnosis of LTBI?

Interferon-gamma release assay (IGRA): QuantiFERON®-TB Gold (Plus)

Interferon-gamma release assay (IGRA): T-SPOT®.TB

Tuberculin Skin Test (TST) / Mantoux

Not applicable

On average, how many TB tests does your practice perform a month?

Yes, I want to be the first to hear about offers and news from QIAGEN

I hereby give QIAGEN the consent to contact me via email and phone (subject to the contact information provided above) with further special offers, contests and product information.

BANT_Budget*

For SP creation / could be hidden field

BANT_Authority*

For SP creation / could be hidden field

BANT_Need*

For SP creation / could be hidden field

BANT_Time*

For SP creation / could be hidden field

Product Line Interest

Primary Campaign Source

For SP creation / could be hidden field

Specific Interest

Lead Source - Most Recent*

For SP creation / could be hidden field

Interaction Request*

For SP creation / could be hidden field

Opportunity Type*

For SP creation / could be hidden field

Buying Type

If Opp Type is INSTRUMENT // For SP creation / could be hidden field

Instrument Type

If Opp Type is INSTRUMENT // For SP creation / could be hidden field

Is screening and treatment of latent TB the key to TB elimination?

Tuberculosis continues to threaten the lives of people worldwide as each year 10 million people develop this disease. Join Dr. Zellweger as he discusses the 2019 WHO report, which gives an up-to-date assessment, including the ongoing progress in TB prevention, diagnosis, and treatment. This current global TB report endorses interferon-gamma release assays (IGRAs), like QuantiFERON-TB Gold Plus, for early detection of latent TB (LTBI) and recommends preventative treatment for those who are most at risk. Find out why the WHO report states that global efforts need to be expanded in screening and treatment and the specific actions needed to end the cycle of active TB disease and transmission.

In this webinar, Dr. Jean-Pierre Zellweger, a former chief of the TB clinic at the University Hospital in Lausanne, will summarize the updated 2019 WHO report and the ongoing progress to end the TB epidemic. Dr. Zellweger will also discuss new preventive treatment regimens, the use of IGRAs as a primary screening method before treating and the benefits of modern TB blood testing with QuantiFERON^®-TB Gold Plus – the latest development of IGRA technology - to help reach the End TB Strategy targets.

QuantiFERON-TB Gold Plus (QFT-Plus) is an in vitro diagnostic aid for detection of Mycobacterium tuberculosis infection. QFT-Plus is an indirect test for M. tuberculosis infection (including disease) and is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations. QFT-Plus Package Inserts as well as up-to- date licensing information and product-specific disclaimers can be found at www.QuantiFERON.com.

* Subject to your consent given above, QIAGEN may use your personal information for internal business and marketing purposes. The information will not be sold to any third party. QIAGEN may transfer your personal information to our CRM system (hosted by SalesForce.com, Inc. and Oracle Corp.) solely for the purposes of data hosting and QIAGEN email distribution. You may unsubscribe at any time. Your data will be processed in compliance with applicable privacy laws, including the EU General Data Protection Regulation. For further details, please refer to our Privacy Policy.